Skip to content

The Different Effectiveness of Single Acupoint(PC6 or CV12) vs Matching Acupoints(PC6 and CV12) in Chemotherapy-induced Nausea and Vomiting

The Comparative Study on the Effectiveness of Single Acupoint and Matching Acupoints.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02195908
Enrollment
160
Registered
2014-07-21
Start date
2014-08-31
Completion date
2015-10-31
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

to Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and Vomiting

Brief summary

The purpose of this study is to clarify whether the matching acupoints are more effective than a single point by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .

Interventions

OTHERsingle point Neiguan(PC6) plus antiemetic drug
OTHERmatching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug

Sponsors

National Basic Research Program, China
CollaboratorOTHER
Tianjin University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Be diagnosed as cancer and need to accept chemotherapy. 2. The score of Karnofsky ≥70 3. Patients of either gender and older than 18 years 4. Patients receiving chemotherapy both outpatients and inpatients 5. Patients receiving chemotherapy either the first or multiple cycle, but the patient will be taken in only one time 6. To receive chemotherapy containing cisplatin(DDP≥75mg/m2) or joint chemotherapy programmes of Anthracyclines(Adriamycin≥40mg/m2 or epirubicin≥60mg/m2) 7. Life expectancy≥ 6 months 8. Willing to participate in the study and be randomized into one of the four study groups.

Exclusion criteria

1. To receive radiotherapy and chemotherapy 2. Gastrointestinal tumors 3. Patients with serious liver disease or abnormal hepatorenal function (AST,ACT, and TBIL are 3 times more than normal, BUN and Cr are 2 times more than normal) 4. Presence of cardiac pacemaker 5. Active skin infection 6. Nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte disturbances) 7. Patients unable to provide self-care or communication 8. Nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal obstruction) 9. Brain metastases 10. Women in pregnant and lactating period

Design outcomes

Primary

MeasureTime frame
the frequency of Nausea and Vomiting6days

Secondary

MeasureTime frame
electrogastrogram3 weeks
the assessment of quality of life3 weeks
the assessment of Anxiety and Depression3 weeks
the grading of constipation and diarrhea3 weeks

Other

MeasureTime frame
electrocardiogram3 weeks
hepatic and renal function3 weeks
other adverse effect during the chemotherapy3 weeks
blood routine examination3 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026